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The impact of severe mental illness on healthcare use and health outcomes for people with type 
2 diabetes: a longitudinal observational study in England
Abstract
Background
People with severe mental illnesses (SMI) have reduced life expectancy compared with the general 
population. Diabetes is a major contributor to this disparity with higher prevalence and poorer 
outcomes in people with SMI. 
Aim
To determine the impact of SMI on healthcare processes and outcomes for diabetes. 
Design and setting
Retrospective observational matched nested case-control study using patient records from the Clinical 
Practice Research Datalink linked to Hospital Episode Statistics. 
Methods
We compared a range of healthcare processes (primary care consultations, physical health checks, 
metabolic measurements) and outcomes (prevalence and hospitalisation for cardiovascular disease 
(CVD), and mortality risk) for 2,192 people with SMI and type 2 diabetes (cases) with 7,773 people 
with diabetes alone (controls). Socio-demographics, comorbidity and medication prescription were 
covariates in regression models.
Results 
SMI was associated with increased risk of all-cause mortality (Hazard Ratio [HR]: 1.92; 95% CI: 1.60 
to 2.30) and CVD-specific mortality (HR: 2.24; 1.55 to 3.25); higher physician consultation rates 
(Incidence Rate Ratio [IRR]: 1.15; 1.11 to 1.19); more frequent checks of blood pressure (IRR: 1.02; 
1.00 to 1.05) and cholesterol (IRR: 1.04; 1.02 to 1.06); lower prevalence of angina (Odds Ratio [OR]: 
0.67; 0.45 to 1.00); higher emergency admissions for angina (IRR: 1.53; 1.07 to 2.20) and lower 
elective admissions for ischaemic heart disease (IRR: 0.68; 0.51 to 0.92).
Conclusion
Monitoring of metabolic measurements was comparable for people with diabetes with and without 
SMI. Increased mortality rates observed in SMI may be attributable to under-diagnosis of CVD and 
delays in treatment. 
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The average life expectancy for people with severe mental illnesses (SMI), such as schizophrenia or 
bipolar disorder, is 15 to 20 years less than the general population.1 Higher prevalence of non-
communicable diseases in people with SMI is a key contributor to this disparity,2-5 partly driven by 
socio-economic disadvantage, health risk behaviours 6,7 and side effects of medications.8-10 Coexisting 
SMI and comorbid conditions may interact, with poorer outcomes for both while access to healthcare 
for physical problems may also be more problematic for people with SMI.11
In the UK, the prevalence of type 2 diabetes (T2DM) is twice as high in people with SMI compared 
with the general population,12 with an increased incidence of acute metabolic emergencies and 
diabetes complications.13,14 National guidelines therefore recommend regular screening for diabetes in 
people with SMI, with the aim of achieving the same standards of care as for the general 
population.15-19 The UK’s primary care pay-for-performance programme, the Quality and Outcomes 
Framework (QOF), has included quality targets for both diabetes and SMI since 2004.20 
Overall recorded quality of care for diabetes has improved substantially following the introduction of 
national quality improvement initiatives.21 However, evidence is lacking on the appropriateness and 
effectiveness of universal quality targets in sub-groups of people with diabetes, including those with 
SMI, and little is known about how SMI and other risk factors combine to affect diabetes outcomes. 
We therefore used a linked healthcare dataset to investigate, in people with diabetes, the impact of 
SMI on healthcare processes and diabetes outcomes including the use of routine primary care 
services, metabolic monitoring, the diagnosis and hospitalisation for cardiovascular disease (CVD), 
and the risk of mortality. We aimed to identify the potential elements in the care pathway that might 
be associated with increased risk of mortality in people with SMI.
Data and methods
Data sources and participants
The dataset was extracted from Clinical Practice Research Datalink (CPRD) GOLD. Patient 
information includes symptoms and diagnoses, referrals to specialists and secondary care settings, 
prescriptions issued in primary care, diagnostic testing, biometric data and other types of care as 
routinely provided in primary care. Patient characteristics are broadly representative of the general 
UK population in terms of age, sex and ethnicity.22 Individual patient data were electronically linked 
to external data sources including Hospital Episode Statistics (HES) for hospital admissions, Office 
for National Statistics (ONS) for death records and the Index of Multiple Deprivation (IMD) for area 
deprivation.23-25
We used a matched nested case-control design. Cases were people with comorbid SMI and diabetes; 
people with diabetes but no SMI were identified as matched controls based on age, sex and primary 
care practice with a maximum ratio of 4:1. SMI was defined by the presence of at least one diagnostic 
record entry for schizophrenia, schizoaffective disorder, bipolar disorder, depression or other affective 
disorder with psychosis in either primary care or hospital admission data. Diabetes was classified by 
the presence of diagnostic codes for T2DM in primary care or hospital admission data. Cases and 
controls were included if their health records were up to research standard (UTS), eligible for relevant 
linkages, and were: i) registered with a participating primary care practice in England in the study 
period from 1 April 2000 to 31 March 2016; ii) aged 18+ when diagnosed; iii) continuous; and iv) 
nested within a matched case-control cluster. 
Individual follow-up periods started on the later date of T2DM diagnosis or the beginning of UTS 
































Follow-up ended on the earlier date of 31 March 2016 or the end of UTS data (Supplementary 
Figure S1). 
Variables 
The exposure variable was SMI diagnosis. Outcome variables were primary care consultations, 
completion of physical health checks, metabolic measurements, diagnosis and hospitalisation for 
CVD, and risk of all-cause and CVD-specific mortality. 
Primary care consultation rates were expressed as the average number of face-to-face consultations 
per year in the follow-up with practice-based health professionals. The average number of health 
checks per year was calculated as recorded checks on blood pressure, serum cholesterol, HbA1c and 
body mass index (BMI) as incentivised under QOF for people with T2DM. Metabolic measurements 
were expressed by the average levels of blood pressure, serum cholesterol and HbA1c in the study 
period. 
CVD was identified as the presence of diagnostic codes recorded in primary care data during the 
follow-up, with separate indicators for angina, myocardial infarction (MI, including acute coronary 
syndrome), stroke, chronic ischaemic heart disease (IHD), as well as a combined indicator for 
macrovascular complications (MI, stroke and peripheral vascular disease (PVD)). Hospital admissions 
for CVD were measured as the average number of admissions per year in the follow-up, separated by 
emergency and elective admissions, as well as by diagnosis groups including angina, MI, chronic IHD 
and stroke.  
We adjusted for age, ethnicity and area deprivation obtained by linking people’s residential postcodes 
to the 2010 English Indices of Multiple Deprivation (IMD) at the Lower Layer Super Output Area 
(LSOA) level, and dividing into quintiles. Baseline comorbidities were measured by the diagnosis of 
CVD, hypertension, dementia, learning disability and the number of Charlson Index comorbidities 
(excluding diabetes and diabetes complications) prior to follow-up. Baseline medication use was 
measured by at least one prescription issued in the 15-month window prior to follow-up for 
antihypertensive, antidiabetes, lipid lowering medications, antidepressants and antipsychotics (first 
and second generations). Baseline smoking status (as a health risk behaviour) and biometric measures 
(BMI, blood pressure, serum cholesterol and HbA1c) were constructed using the most recent records 
extracted from the 15-month window. 
Statistical methods 
A case-control cluster entered the analysis only after the ‘case’ was diagnosed with SMI. We applied 
‘within’ estimators in our regressions to only examine the variations in outcomes among matched 
individuals. Conditional logistic regression models, Poisson or negative binomial models and 
stratified Cox proportional hazard models were applied depending on the type of outcome variables. 
Status of SMI was treated as time-dependent in survival analyses, and the proportional hazard 
assumption was tested by the inclusion of interaction effects between explanatory variables and time – 
interaction terms with significant coefficients were retained in the final models. Goodness of fit was 
assessed by the C-statistic, the Akaike information criterion (AIC) and Bayesian information criterion 
(BIC) as appropriate. Due to the extent of missing data, family history of diabetes, smoking status and 
baseline biometrics were retained in the model only if they improved model fit. Further adjustments 
were made to account for duration of T2DM, death during follow-up, length of follow-up and 


































Baseline characteristics of people with and without SMI are summarised in Tables 1-2. A total of 
2,192 people with SMI (cases) were matched to 7,773 people without SMI (controls): 88% of cases 
matched to 3-4 controls, 53% of cases had schizophrenia and 32% bipolar disorder. People with SMI 
were similar to people without SMI for age, sex, duration of T2DM and follow-up length, but were 
more likely to live in the most deprived neighbourhoods, have dementia or learning disability, and 
less likely to have physical comorbidities recorded. People with SMI were also more likely to be 
prescribed antidepressants and antipsychotics, and less likely to be prescribed antihypertensive and 
lipid lowering medications.
Proportions of missing values were generally similar between people with and without SMI for 
smoking status and biometric variables, with BMI and smoking slightly better recorded for people 
with SMI. On average, people with SMI had higher BMI and levels of serum cholesterol and lower 
HbA1c and blood pressure. 
Crude outcomes for these two groups are summarised in Table 3. People with SMI had, on average, a 
higher number of contacts with primary care and received more health checks for BMI compared with 
those without SMI. The crude consultation rate was 13.7 per year for people with SMI including 9.0 
contacts with primary care physicians and 4.7 with practice nurses. Rates were respectively 11.2, 6.9 
and 4.3 per year for people without SMI. Frequency of health checks for HbA1c and cholesterol were 
similar in both groups, whereas blood pressure checks were less likely for people with SMI.
For CVD, people with SMI had lower crude risks for MI, PVD, angina, chronic IHD and 
macrovascular complications. The crude prevalence of stroke was higher in people with SMI than in 
people without SMI. Hospital admission rates for these conditions were similar between the groups, 
with emergency admission rate slightly higher in those with SMI. All-cause and CVD-specific crude 
mortality rates were higher in people with SMI. 
Average serum cholesterol and HbA1c levels declined between 2000/01 and 2006/7 for both groups, 
and then remained relatively stable thereafter. Average blood pressure levels declined throughout the 
study period, and people with SMI had lower levels at all time points (Figure 1). 
Regression analyses 
The adjusted impact of SMI on outcomes is summarised in Table 4. People with SMI had higher 
primary care consultation rates and were more likely to receive checks for blood pressure, cholesterol 
and BMI. The estimated increase was 10% (Incidence Rate Ratio [IRR]: 1.10; 95% CI: 1.07 to 1.13) 
for overall consultations, and 15% (IRR: 1.15; 1.11 to 1.19) for contacts with primary care physicians. 
Checks were increased by 2% (IRR: 1.02; 1.00 to 1.05) for blood pressure, 4% (IRR: 1.04; 1.02 to 
1.06) for cholesterol and 7% (IRR: 1.07; 1.04 to 1.09) for BMI for people with SMI compared with 
those without SMI. 
People with SMI were less likely to have a primary care diagnosis of angina (Odds Ratio [OR]: 0.67; 
0.45 to 1.00) but more likely to have a diagnosis of stroke (OR: 1.38; 1.04 to 1.84). For emergency 
admissions, people with SMI had varied risks for different types of CVD, including increased risk for 
angina (IRR: 1.53; 1.07 to 2.20) and stroke (IRR: 1.44; 1.06 to 1.97) and decreased risk for MI (IRR: 
0.68; 0.48 to 0.97). These people were less likely to have an elective admission for CVD (IRR: 0.64; 
0.47 to 0.88) and had lower admission rates for chronic IHD (IRR: 0.68; 0.51 to 0.92) compared with 































The all-cause mortality rate was 92% higher (Hazard Ratio [HR: 1.92]; 1.60 to 2.30) and CVD-
specific mortality rate 124% higher (HR: 2.24; 1.55 to 3.25) in people with SMI compared with 
people without this condition.   
Full results of adjusted models are provided in Supplementary Tables S1-S6. Predictors for more 
frequent consultations were deprivation, longer duration of T2DM, comorbidity, and some 
medications. Dementia was associated with fewer consultations. Higher frequencies of health checks 
were associated with less deprived status (for cholesterol and HbA1c checks), Charlson comorbidities, 
use of medications, obesity, family history of diabetes, and higher biometric measures at baseline.  
History of CVD and use of lipid lowering medications were the strongest predictors for future CVD 
events such as hospital admissions. Baseline antihypertensive prescriptions were associated with 
increased risk of hospital admission for angina and stroke. Longer duration of T2DM was associated 
with increased risk of CVD admissions, whilst deprivation, history of CVD and the presence of 
comorbidities were associated with increased risk of all-cause mortality.
Discussion
Summary
After adjusting for confounders, we found no evidence that people with SMI and diabetes experienced 
reduced access to routine primary care such as consultations and physical health checks than people 
with diabetes alone. People with SMI were, however, more likely to be socio-economically 
disadvantaged and to have some recorded conditions (e.g. dementia), and less likely to have others 
(e.g. physical comorbidity).  Despite this, there were complex associations between SMI and the risk 
of CVD outcomes across diagnosis groups and healthcare settings. Recorded prevalence of angina 
was lower for people with SMI, as were elective hospital admission rates for CVD and emergency 
admission rates for MI. In contrast, emergency hospital admission rates for angina and stroke were 
substantially higher. Finally, people with SMI were more likely to die compared with those without 
SMI, with more than double the risk of CVD-related mortality.
Strengths and limitations
We analysed a large, linked longitudinal dataset of individual primary care records, allowing study of 
multiple elements along the care pathway for diabetes and CVD, and our matched nested case-control 
study design and application of ‘within’ estimators reduced the impact of unobserved confounders. 
Our interrogation of multiple diagnosis groups can be considered as sensitivity checks of our key 
findings, and the adjustment of medication prescriptions has improved the identification of 
comorbidities, particularly for the physical long-term conditions in people with SMI. Furthermore, 
patient characteristics in this database have been shown to be broadly representative of the general 
UK population in terms of age, sex and ethnicity,22 meaning our findings are likely to have wider 
generalisability. 
As with all studies using routine healthcare records, data accuracy and completeness create 
limitations.  There were high levels of missing data for some variables and we could not adjust for 
factors such as lifestyle, environmental and social determinants of health. Coding behaviour is likely 
to vary by individual primary care staff and practices, presenting further potential errors in primary 
care records. Under QOF, however, primary care providers have been incentivised to maintain 
































affected by this limitation compared with other areas. Data on pathways, including referral and 
outpatient records, were limited; this restricted our exploration of service use along the full care 
pathway and potential service gaps. Severity of mental illness or diabetes is not routinely recorded 
and could not be inferred reliably. Heart failure, which is more common in people with diabetes, has 
not been analysed. As with all observational studies, it was not possible to control for unobserved 
confounders and systematic measurement biases which might lead us to over- or under-estimate 
associations between risk factors and outcomes. 
Comparison with existing literature
Our analysis of both primary care and hospital admission records has highlighted two potential 
inequalities in the identification and subsequent treatment of CVD. First, diagnosis of angina in 
primary care was lower in people with SMI, but emergency admission rates were higher. This may 
reflect more rapid and severe onset, presentation and diagnostic delay, and/or greater preference for 
emergency hospital services as the first contact point for people with SMI experiencing chest pain. 
The lower admission rate for MI might be related to this and suggest fewer but more fatal admissions 
for coronary heart disease, rather than an indicator of better outcomes. Second, the lower diagnosis 
and elective admission rates for IHD in people with SMI suggests that this population was less likely 
to be referred to cardiovascular specialist care, a finding consistent with an Australian study.26 
Elective admissions for IHD were mainly accessed through referrals by primary care physicians, 
either for initial clinical investigation (e.g. coronary arteriography) or for carrying out invasive 
procedures (e.g. CABG and stent insertion) following an emergency admission for MI. These findings 
agree with an existing literature5 that people with SMI may under-use both investigations and invasive 
procedures due to under-diagnosis of coronary heart disease.
There are several inter-related potential explanations. Reasons for systematic under-diagnosis of CVD 
could include symptom underreporting by people with SMI, diagnostic overshadowing and a lack of 
confidence by mental health professionals to diagnose and manage physical comorbidities.27 Primary 
care providers might be reluctant to prescribe medications for long-term conditions and refer people 
with SMI for standard surgical procedures,28,29 perhaps due to perceived  psychological stress, 
capacity for post-operative care and a higher risk of developing complications after surgical 
interventions. A lack of integration among primary care, specialist physical healthcare and psychiatric 
services may have made navigation of the care pathway more difficult for people with SMI.30,31
Implications for research and practice
Our analysis shows that the greatest challenge is no longer general monitoring of metabolic risk 
factors as incentivised by national guidelines, as these now appear to be equally delivered to people 
with and without SMI. Rather, people with SMI appear to be under-diagnosed for cardiovascular 
disease in primary care and consequently have poorer access to specialist and elective hospital care, 
leading to an elevated risk of cardiovascular mortality in this population. Policies to reduce excess 
deaths should therefore focus on activities earlier along the care pathway to facilitate early diagnosis 
and timely treatment for CVD. Furthermore, current QOF targets do not consider the implications of 
antipsychotic medication and other unique challenges people with SMI face in managing their 
diabetes. Living in more deprived circumstances, as seen in this study, can also increase the likelihood 
of developing chronic health problems, and reduce capacity to successfully manage them. Policies 
should be designed to encourage primary care providers to initiate effective conversations with 
patients and carers on both mental and physical health needs; improve coordination between primary 
care and specialist physical healthcare services; and develop strategies for tackling the particular 
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How this fits in
People with severe mental illnesses (SMI) have poorer physical health and a lower life 
expectancy by around 20 years than the general population, mostly due to comorbid non-
communicable diseases. Diabetes contributes significantly to this health inequality through 
multiple mechanisms including a 2-3 times higher prevalence, increased incidence of diabetes 
complications, and its interaction with SMI in aspects of health behaviours, access to health 
services and effectiveness of treatments. National guidelines have recommended regular 
screening for diabetes in people with SMI and monitoring of metabolic risk factors in people with 
diabetes. This study has provided new evidence that monitoring of diabetes and metabolic control 
is no worse for people with SMI and diabetes compared to people with diabetes alone. However, 
people with SMI are under-diagnosed for cardiovascular disease in primary care and 
consequently have poorer access to specialist and elective hospital care, which might explain the 
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No. of participants, N (%) 9,965 (100%) 2,192 (22.0%) 7,773 (78.0%)
No. of controls per case, n (%)
4 controls 1,599 (73.0%)
3 controls 323 (14.7%)
2 controls 138 (6.3%)
1 control 132 (6.0%)
Diagnosis age, mean (SD)
SMI 47.98 (17.40)
T2DM 57.83 (12.97) 56.81 (13.19) 58.12 (12.89)
SMI type, n (%)
Schizophrenia 1,161 (53.0%)
Schizoaffective disorder 113 (5.2%)
Bipolar disorder 701 (32.0%)
Depression and psychosis 184 (8.4%)
Other affective disorder 26 (1.2%)
Mixed 7 (0.3%)
Age at follow-up start, mean (SD) 58.63 (12.83) 57.67 (13.11) 58.90 (12.74)
Duration of T2DM (years), mean (SD) 0.82 (2.85) 0.89 (3.02) 0.80 (2.80)
Follow-up length (years), mean (SD) 6.19 (4.43) 6.02 (4.45) 6.23 (4.43)
Family history of diabetes, n (%) 1,766 (17.7%) 324 (14.8%) 1,442 (18.6%)
Sex, n (%)
Male 4,758 (47.8%) 1,051 (48.0%) 3,707(47.7%)
Female 5,207 (52.3%) 1,141 (52.1%) 4,066 (52.3%)
Ethnicity, n (%)
White 8,095 (81.2%) 1,826 (83.3%) 6,269 (80.7%)
Asian 638 (6.4%) 139 (6.3%) 499 (6.4%)
Black 363 (3.6%) 106 (4.8%) 257 (3.3%)
Mixed, other and unknown 869 (8.7%) 121 (5.5%) 748 (9.6%)
Deprivation (IMD 2010), n (%)
1st quintile (lease deprived) 1,490 (15.0%) 279 (12.7%) 1,211 (15.6%)
2nd quintile 1,860 (18.7%) 358 (16.3%) 1,502 (19.3%)
3rd quintile 1,984 (19.9%) 415 (18.9%) 1,569 (20.2%)
4th quintile 2,287 (23.0%) 542 (24.7%) 1,745 (22.5%)
5th quintile 2,334 (23.4%) 595 (27.1%) 1,739 (22.4%)








































Cardiovascular disease 1,591 (16.0%) 285 (13.0%) 1,306 (16.8%)
Hypertension 4,318 (43.3%) 734 (33.5%) 3,584 (46.1%)
Dementia 64 (0.6%) 32 (1.5%) 32(0.4%)
Learning disability 40 (0.4%) 19 (0.9%) 21 (0.3%)
Charlson, mean (SD) 0.53 (0.78) 0.49 (0.73) 0.54 (0.79)
Medications, n (%)
Antidepressants 2,585 (25.9%) 1,062 (48.5%) 1,523 (19.6%)
Antipsychotics
1st generation 524 (5.3%) 434 (19.8%) 90 (1.2%)
2nd generation 1,009 (10.1%) 957 (43.7%) 52 (0.7%)
Antidiabetes 2,164 (21.7%) 521 (23.8%) 1,643 (21.1%)
Antihypertensives 5,349 (53.7%) 1,000 (45.6%) 4,349 (56.0%)
Lipid lowering drugs 3,361 (33.7%) 684 (31.2%) 2,677 (34.4%)
Smoking, n (%)
Non-smoker 2,775 (27.9%) 544 (24.8%) 2,231 (28.7%)
Ex-smoker 2,049 (20.6%) 390 (17.8%) 1,659 (21.3%)
Current smoker 1,873 (18.8%) 650 (29.7%) 1,223 (15.7%)
Missing 3,268 (32.8%) 608 (27.7%) 2,660 (34.2%)
Biometric measures, n (%)
BMI, mean (SD) 32.66 (6.95) 32.97 (6.99) 32.56 (6.94)
< 20 kg/m2 62 (0.6%) 12 (0.6%) 50 (0.6%)
20 – 24 kg/m2 617 (6.2%) 145 (6.6%) 472 (6.1%)
25 – 29 kg/m2 1,752 (17.6%) 401 (18.3%) 1,351 (17.4%)
30+ kg/m2 3,004 (30.2%) 733 (33.4%) 2,271 (29.2%)
40+ kg/m2 871 (8.7%) 221 (10.1%) 650 (8.4%)
 Missing 3,659 (36.7%) 680 (31.0%) 2.979 (38.3%)
HbA1c (%, mmol/mol), mean (SD) 7.88 (1.95) 7.82 (1.99) 7.90 (1.95)
≤ 7.5% (58 mmol/mol) 2,998 (30.1%) 672 (30.7%) 2,326 (29.9%)
> 7.5% (58 mmol/mol) 2,188 (22.0%) 460 (21.0%) 1,728 (22.2%)
Missing 4,779 (48.0%) 1,060 (48.4%) 3,719 (47.9%)
Total Cholesterol (mmol/L), mean (SD) 5.30 (1.31) 5.36 (1.42) 5.28 (1.28)
≤ 5 mmol/L 3,477 (34.9%) 722 (32.9%) 2,755 (35.4%)
> 5 mmol/L 4,105 (41.2%) 892 (40.7%) 3,213 (41.3%)
Missing 2,383 (23.9%) 578 (26.4%) 1,805 (23.2%)
BP systolic (mmHg), mean (SD) 139.17 (18.28) 135.82 (18.16) 140.13 (18.21)
≤ 140 mmHg 5,154 (51.7%) 1,280 (58.4%) 3,874 (49.8%)
> 140 mmHg 3,306 (33.2%) 605 (27.6%) 2,701 (34.8%)
Missing 1,505 (15.1%) 307 (14.0%) 1,198 (15.4%)
BP diastolic (mmHg), mean (SD) 81.87 (10.72) 81.47 (10.72) 81.99 (10.71)
≤ 80 mmHg 4,391 (44.1%) 1,011 (46.1%) 3,380 (43.5%)
> 80 mmHg 4,069 (40.8%) 874 (39.9%) 3,195 (41.1%)






































Primary care consultations (per year)
Overall
Mean (SD) 11.72 (10.05) 13.65 (10.07) 11.18 (9.97)
Median (min, max) 9.60 (0, 365.30a) 11.10 (0, 113.00) 9.20 (0, 365.30a)
Primary care physicians
Mean (SD) 7.32 (7.77) 8.98 (7.83) 6.85 (7.69)
Median (min, max) 5.70 (0, 365.30a) 7.10 (0, 91.30) 5.30 (0, 365.30a)
Practice Nurses 
Mean (SD) 4.40 (5.29) 4.67 (5.26) 4.32 (5.30)
Median (min, max) 3.30 (0, 143.40) 3.40 (0, 68.30) 3.20 (0, 143.40)
Health checks (per year)
HbA1c
Mean (SD) 1.80 (1.16) 1.78 (1.27) 1.81 (1.13)
Median (min, max) 1.70 (0 - 45.70) 1.70 (0 - 28.10) 1.70 (0 - 45.70)
Blood pressure
Mean (SD) 3.01 (4.27) 2.93 (2.49) 3.03 (4.66)
Median (min, max) 2.60 (0 - 365.30a) 2.50 (0 - 52.20) 2.60 (0 - 365.30a)
Total Cholesterol
Mean (SD) 1.35 (0.86) 1.38 (0.97) 1.35 (0.82)
Median (min, max) 1.30 (0 - 26.10) 1.30 (0 - 26.10) 1.30 (0 - 13.50)
BMI
Mean (SD) 1.98 (4.07) 2.08 (1.95) 1.95 (4.49)
Median (min, max) 1.60 (0 - 365.30a) 1.70 (0 - 30.40) 1.60 (0 - 365.30a)
Macrovascular complications (combined), n (%) 868 (8.7%) 184 (8.4%) 684 (8.8%)
MI 344 (3.5%) 70 (3.2%) 274 (3.5%)
PVD 305 (3.1%) 58 (2.7%) 247 (3.2%)
Stroke 293 (2.9%) 72 (3.3%) 221 (2.8%)
Angina 324 (3.3%) 55 (2.5%) 269 (3.5%)
Chronic IHD 101 (1.0%) 17 (0.8%) 84 (1.1%)
Hospital admissions for cardiovascular disease 
(per year), mean (SD)
Emergency 0.03 (1.20) 0.03 (0.25) 0.02 (0.18)
Elective 0.01 (0.15) 0.01 (0.05) 0.01 (0.16)
Angina (I20b) 0.01 (0.06) 0.01 (0.06) 0.01 (0.07)
MI (I21&I22b) 0.01 (0.17) 0.01 (0.24) 0.01 (0.15)
Chronic IHD (I25b) 0.01 (0.15) 0.01 (0.05) 0.01 (0.17)
Stroke (I60 - I64b) 0.01 (0.07) 0.01 (0.08) 0.01 (0.07)
Mortality - all causes, n (%) 1,384 (13.9%) 364 (16.6%) 1,020 (13.1%)
Mortality – CVD, n (%) 511 (5.1%) 132 (6.0%) 379 (4.9%)
a. High consultation and health check rates reflected few consultations recorded over a short follow-up. b. ICD-10 codes used to classify 













































































































































































































































Table 4. Adjusted impact of SMI on healthcare use and health outcomes.
 Diagnosis of SMI
 Adjusted IRRa 95% CI p value
Primary care consultations
Overall 1.101 [1.069 - 1.134] < 0.001
Primary care physicians 1.149 [1.111 - 1.188] < 0.001
Practice Nurses 1.020 [0.982 - 1.060] 0.297
 Adjusted IRRa 95% CI p value
Physical health checks
Blood pressure 1.024 [1.003 - 1.046] 0.028
Cholesterol 1.038 [1.019 - 1.058] < 0.001
HbA1c 0.989 [0.970 - 1.009] 0.297
BMI 1.068 [1.044 - 1.093] < 0.001
 Adjusted IRRa 95% CI p value
Hospital admissions for cardiovascular disease (I20-25&I60-
69)
Emergency 1.149 [0.959 - 1.378] 0.132
Angina (I20) 1.532 [1.069 - 2.195] 0.020
MI (I21&I22) 0.683 [0.482 - 0.967] 0.032
Stroke (I60-I64) 1.440 [1.055 - 1.965] 0.022
Elective 0.644 [0.470 - 0.882] 0.006
Chronic IHD (I25) 0.682 [0.508 - 0.915] 0.011
 Adjusted ORb 95% CI p value
Primary care diagnosis of cardiovascular disease
Macrovascular complications (MI, stroke and PVD) 0.970 [0.794 - 1.185] 0.765
Angina 0.671 [0.450 - 1.001] 0.050
MI 0.929 [0.698 - 1.236] 0.613
Stroke 1.381 [1.036 - 1.841] 0.028
Chronic IHD 0.742 [0.394 - 1.399] 0.356
 Adjusted HRc 95% CI p value
Mortality
All-cause 1.919 [1.602 - 2.300] < 0.001
Cardiovascular disease 2.242 [1.547 - 3.250] < 0.001
Robust 95% CI in brackets. a. Incidence rate ratio (IRR); b. Odds ratio (OR); c. Hazard ratio (HR). Models were adjusted for age, ethnicity, 
deprivation, financial years and statistically significant confounders in comorbidities, medications use, duration and family history of 
T2DM, death in follow-up, smoking and biometric measures.
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